bioMérieux stock rebounds by nearly 3% against the grain of the SBF 120
In a European market oriented downward this Monday, bioMérieux stands out as an exception and ranks among the best performances of the SBF 120. The rebound occurs as the stock remains under pressure over a year and attempts to hold at a key technical level.
A rebound of 2.84% that brings the stock back into contact with its 50-day moving average despite selling pressure in the market
bioMérieux gains 2.84% during the session at €72.40, in an SBF 120 that falls 0.77% and a CAC 40 declining 0.78%. This rebound contrasts with the decline recorded Monday, September 7, when the stock fell back to the bottom of the index ranking. Over the past week, the balance remains slightly negative at -2.49%, and the one-year performance remains weighed down at -37.1%, a gap that reflects a deep correction initiated well before this session.
One-month volatility remains elevated at 8.90, in a context of markets shaken by a busy week of central bank decisions: the Fed meets on Wednesday, the Bank of England on Thursday. The VIX, meanwhile, surges more than 14% during the session, reflecting overall nervousness that makes the rebound of the diagnostics stock even more notable.
Support at the 50-day moving average at €72.38 in a fundamental context that confirms 2026 outlook
In terms of price levels, bioMérieux is trading exactly at the level of its 50-day moving average at €72.38, with a difference of only +0.03%. This average is today the central axis of the session: above it, the 20-day moving average at €73.74 forms a first resistance to overcome, while support at €69.10 remains in the background. The RSI at 37 is approaching the oversold zone without reaching it, signaling persistent selling momentum on the back of technical recovery. The resistance at €75.80, already tested in early September, remains the medium-term objective to watch.
On the fundamental side, when publishing the first half of 2026 on August 4, the group had confirmed its annual outlook: organic revenue growth of +3% to +5% and CEBIT progression between 0% and +10%. The four drivers of the GO•28 plan showed organic growth of 6%, while the FDA filing of the SPOTFIRE® Vaginitis panel and the obtaining of CE marking for the first SPINCHIP® test illustrated portfolio advancement. The resistance at €75.80 remains the next structural level to observe.
